BLOOD MANAGEMENT UNIVERSITY® - Live Learning Webinar Series

Transfusion adverse events & biological product deviations: what you need to report

Today is the last day to register for this webinar!

October 6, 2011, 1 – 2 pm EDT

Presented by: Mary A Lieb MT(ASCP) SBB, CQA(ASQ)
Director, Quality Source, Blood Systems
Scottsdale, AZ

A preview, direct from the presenter:

Q:  Ms. Lieb, how did you become interested in the topic of adverse events associated with transfusions?

A:  As a medical technologist working in transfusion service reporting, errors resulting in mis-transfusion have always been a concern. To be a good steward of the blood supply, you have to make sure your processes minimize error. The only way to do that is to report, monitor, track, and trend errors as well as recognize those that must be reported to the FDA for compliance.

Q:  What has been the biggest surprise in your observations?

A:.  Recognizing what is an actual adverse event that needs to be reported to the blood bank, as well as what must be reported to the FDA when errors are made that do NOT result in death but loss of control of the process or product.

Q:  What are two reasons other physicians and healthcare providers should care about reporting and adverse events surrounding transfusion?

A:  Awareness/recognition, and compliance with the federal regulations which carry the weight of law.

Cost: 30.00

To register as an individual: click here
To register as a group:        click here

Claim your spot by tonight, 8 pm, Oct. 3, 2011.  Note:  Participation is limited; first-come, first-served.

--  Next webinar:  Join us on Oct. 20, 2011 at 1 pm EDT for another instructive webinar:

Managing Patients Who Refuse Blood Transfusion Therapy

Presented by: Aryeh Shander, MD
Chief of Anesthesiology, Critical Care Medicine & Hyperbaric Medicine
Englewood Hospital & Medical Center
Englewood, NJ

Abstract
Blood transfusion has long been an integral part of modern medicine. Despite lack of attempts at evaluating the value of transfusion as a therapeutic intervention, its use has rarely been questioned.  When the first global epidemic of HIV struck, rather than undertaking a calculated risk-benefit analysis, all efforts and resources went to improve the “safety” of the product.

Not until the 1990’s did a systematic approach develop for treating patients for whom blood was not an option.  While we think of primarily those of the Jehovah’s Witness faith as patients for whom blood is not an option, in fact, other patients may be in a similar position for an entirely different reason.

The lion’s share of civilian experience in care without blood is within the Witness community.  Religious conviction is their reason for not accepting major blood components, regardless of the outcome.  Not having the option of transfusions, some healthcare providers developed an approach to treating both hemostatic defects and even life- threatening anemia with complete survival.  This experience was quickly shared with all patients, thus reducing their exposure to banked blood while demonstrating equal or better outcomes than with transfusion.

As both pharmaceuticals and devices improve with time, and newer agents are introduced to clinical practice, the chasm between patients accepting transfusion and those who decline it will narrow and close

Cost: 30.00

To register as an individual:           click here
To register as a group:                  click here